RecruitingEarly Phase 1NCT06216938
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Studying Isolated femoral agenesis/hypoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yana Najjar
- Principal Investigator
- Yana Najjar, MDUPMC Hillman Cancer Center
- Intervention
- Vusolimogene oderparepvec (RP1)(biological)
- Enrollment
- 25 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (1)
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Collaborators
Replimune, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06216938 on ClinicalTrials.govOther trials for Isolated femoral agenesis/hypoplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07539792Efficacy and Safety Evaluation of Absorbable and Moldable Skull Base Support Plates in Extended Endoscopic Endonasal Transsphenoidal Surgery: A Prospective, Randomized, Controlled StudyNanfang Hospital, Southern Medical University
- ACTIVE NOT RECRUITINGNCT07151794G8, CARG, Frailty, and Nutritional Markers in Predicting ChemotoxicityÇanakkale Onsekiz Mart University
- RECRUITINGNCT06164483Auditory Functions in Patients With Multiple SclerosisUniversity of Catania
- RECRUITINGPHASE2NCT05817214Cadonilimab Plus Anlotinib for R/M/P Cervical CancerZhongnan Hospital
- ENROLLING BY INVITATIONNANCT04498026Adherus™ Dural Sealant in Spinal ProceduresStryker Craniomaxillofacial
- RECRUITINGNANCT04099823MR Evaluation of Cerebrospinal Fluid (CSF) DynamicsMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT03866525OH2 Oncolytic Viral Therapy in Solid TumorsBinhui Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT04386967OH2 Injection in Solid TumorsBinhui Biopharmaceutical Co., Ltd.